The TARGET Osteosarcoma project elucidates comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of high-risk or hard-to-treat childhood cancers.

Osteosarcoma (OS) is the most common type of bone cancer in children and adolescents. It is most frequently diagnosed in adolescent patients experiencing periods of rapid growth. As with other childhood cancers being studied by TARGET, improvements in survival outcomes for OS have plateaued despite attempts in refining the standard treatment protocol. Additionally, patients endure rigorous therapy regimens regardless of whether the disease is localized or metastatic. Thus, targeted therapies have the potential to enhance the survival and quality-of-life of patients with this disease. To learn more about Osteosarcoma and current treatment strategies, visit the NCI osteosarcoma website.

As of September 1, 2019, the National Cancer Institute removed the restrictions limiting investigators from publishing broad results using osteosarcoma data from the TARGET initiative. OS datasets are available without restrictions on their use in publications or presentations.

Last updated: October 09, 2019